Morgan Stanley Maintains Equal-Weight on Prime Medicine, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Prime Medicine (NASDAQ:PRME) and lowered the price target from $21 to $19.
August 14, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Prime Medicine and lowered the price target from $21 to $19.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100